{"id":56393,"date":"2026-02-05T20:15:40","date_gmt":"2026-02-05T12:15:40","guid":{"rendered":"https:\/\/flcube.com\/?p=56393"},"modified":"2026-02-05T20:15:41","modified_gmt":"2026-02-05T12:15:41","slug":"abbvie-immunology-portfolio-drives-61-2b-revenue-in-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56393","title":{"rendered":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025"},"content":{"rendered":"\n<p><strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE:\u202fABBV<\/a>) reported fourth\u2011quarter revenue of <strong>USD\u202f16.618\u202fbillion<\/strong>, up <strong>9.5% year\u2011on\u2011year (YOY)<\/strong>, bringing full\u2011year 2025 revenue to <strong>USD\u202f61.16\u202fbillion<\/strong>, an <strong>8.5% YOY increase<\/strong>. The <strong>immunology portfolio<\/strong> was the primary growth driver, generating <strong>USD\u202f30.406\u202fbillion<\/strong> (+14% YOY), led by <strong>Skyrizi (risankizumab)<\/strong> with <strong>USD\u202f17.562\u202fbillion<\/strong> in sales (+49.7%).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-segment-performance-summary\">Financial &amp; Segment Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>2025 Revenue (USD\u202fB)<\/th><th>YOY Growth<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Immunology<\/strong><\/td><td>30.406<\/td><td>+14%<\/td><td>Skyrizi (+49.7%), strong biologics demand<\/td><\/tr><tr><td><strong>Neuroscience<\/strong><\/td><td>10.767<\/td><td>+19.4%<\/td><td>Growth in migraine\/psychiatry<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>6.655<\/td><td>+1.4%<\/td><td>Steady performance<\/td><\/tr><tr><td><strong>Aesthetics<\/strong><\/td><td>4.86<\/td><td>-5.9%<\/td><td>Market softness<\/td><\/tr><tr><td><strong>Eye Care<\/strong><\/td><td>2.109<\/td><td>-5.5%<\/td><td>Competitive pressure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-developments\">Strategic Developments<\/h2>\n\n\n\n<p><strong>Government Agreement &amp; Investment:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reached <strong>U.S. government agreement<\/strong> for lower Medicaid prices<\/li>\n\n\n\n<li>Committed <strong>USD\u202f100\u202fbillion<\/strong> in U.S. R&amp;D and capital investments over next decade<\/li>\n\n\n\n<li>Secured <strong>tariff and pricing restriction exemptions<\/strong> for three\u2011year term<\/li>\n<\/ul>\n\n\n\n<p><strong>Manufacturing Expansion:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acquisition agreement<\/strong> with <strong>West Pharmaceutical Services<\/strong> for <strong>Tempe, Arizona<\/strong> device manufacturing facility and IP<\/li>\n\n\n\n<li>Supports production of existing and next\u2011generation immunology and neuroscience drugs<\/li>\n<\/ul>\n\n\n\n<p><strong>Pipeline Expansion:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive licensing agreement<\/strong> with <strong>RemeGen Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688331:SHA\">SHA: 688331<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>) for <strong>PD\u20111\/VEGF bispecific antibody RC148<\/strong><\/li>\n\n\n\n<li>Strengthens AbbVie\u2019s oncology and immuno\u2011oncology portfolio<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding AbbVie\u2019s revenue expectations, strategic initiatives, and commercial prospects. Actual results may differ due to competitive dynamics, regulatory changes, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/ABBV-4Q25-Press-Release-Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ABBV 4Q25 Press Release - Final.\"><\/object><a id=\"wp-block-file--media-aa87457a-ed4c-4127-b4bc-fef12e66f4b7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/ABBV-4Q25-Press-Release-Final.pdf\">ABBV 4Q25 Press Release &#8211; Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/ABBV-4Q25-Press-Release-Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aa87457a-ed4c-4127-b4bc-fef12e66f4b7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56396,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[234,27,1155,853,375,1294],"class_list":["post-56393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-abbvie","tag-finanical-reports","tag-hkg-9995","tag-nyse-abbv","tag-remegen","tag-sha-688331"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025 revenue to USD\u202f61.16\u202fbillion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD\u202f30.406\u202fbillion (+14% YOY), led by Skyrizi (risankizumab) with USD\u202f17.562\u202fbillion in sales (+49.7%).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56393\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025\" \/>\n<meta property=\"og:description\" content=\"AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025 revenue to USD\u202f61.16\u202fbillion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD\u202f30.406\u202fbillion (+14% YOY), led by Skyrizi (risankizumab) with USD\u202f17.562\u202fbillion in sales (+49.7%).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56393\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T12:15:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-05T12:15:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025\",\"datePublished\":\"2026-02-05T12:15:40+00:00\",\"dateModified\":\"2026-02-05T12:15:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0502.webp\",\"keywords\":[\"AbbVie\",\"Finanical Reports\",\"HKG: 9995\",\"NYSE: ABBV\",\"RemeGen\",\"SHA: 688331\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56393#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56393\",\"name\":\"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0502.webp\",\"datePublished\":\"2026-02-05T12:15:40+00:00\",\"dateModified\":\"2026-02-05T12:15:41+00:00\",\"description\":\"AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025 revenue to USD\u202f61.16\u202fbillion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD\u202f30.406\u202fbillion (+14% YOY), led by Skyrizi (risankizumab) with USD\u202f17.562\u202fbillion in sales (+49.7%).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56393\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0502.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56393#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025 revenue to USD\u202f61.16\u202fbillion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD\u202f30.406\u202fbillion (+14% YOY), led by Skyrizi (risankizumab) with USD\u202f17.562\u202fbillion in sales (+49.7%).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56393","og_locale":"en_US","og_type":"article","og_title":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025","og_description":"AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025 revenue to USD\u202f61.16\u202fbillion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD\u202f30.406\u202fbillion (+14% YOY), led by Skyrizi (risankizumab) with USD\u202f17.562\u202fbillion in sales (+49.7%).","og_url":"https:\/\/flcube.com\/?p=56393","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-05T12:15:40+00:00","article_modified_time":"2026-02-05T12:15:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56393#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56393"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025","datePublished":"2026-02-05T12:15:40+00:00","dateModified":"2026-02-05T12:15:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56393"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56393#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp","keywords":["AbbVie","Finanical Reports","HKG: 9995","NYSE: ABBV","RemeGen","SHA: 688331"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56393#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56393","url":"https:\/\/flcube.com\/?p=56393","name":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56393#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56393#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp","datePublished":"2026-02-05T12:15:40+00:00","dateModified":"2026-02-05T12:15:41+00:00","description":"AbbVie Inc. (NYSE:\u202fABBV) reported fourth\u2011quarter revenue of USD\u202f16.618\u202fbillion, up 9.5% year\u2011on\u2011year (YOY), bringing full\u2011year 2025 revenue to USD\u202f61.16\u202fbillion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD\u202f30.406\u202fbillion (+14% YOY), led by Skyrizi (risankizumab) with USD\u202f17.562\u202fbillion in sales (+49.7%).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56393#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56393"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56393#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp","width":1080,"height":608,"caption":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56393#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56393"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56393\/revisions"}],"predecessor-version":[{"id":56398,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56393\/revisions\/56398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56396"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}